Novel roles for the IgG Fc glycan

Annals of the New York Academy of Sciences

Volumn 1253, Issue 1, 2012, Pages 170-180

  Anthony, Robert M ^a   Wermeling, Fredrik ^a   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Autoimmune disease; DC SIGN; Fc receptor; Inflammation; Sialylation

Indexed keywords

ASPARAGINE; AUTOANTIGEN; CD209 ANTIGEN; CYTOKINE; FC RECEPTOR; GLYCAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G FC GLYCAN; MONOSACCHARIDE; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DENDRITIC CELL; DRUG MEGADOSE; HUMAN; IMMUNE MEDIATED THROMBOCYTOPENIA; INFECTION; INFLAMMATION; INFLAMMATORY AUTOIMMUNE DISEASE; LEUKOCYTE ACTIVATION; NEOPLASM; NONHUMAN; RHEUMATOID ARTHRITIS; SIALYLATION; THROMBOCYTOPENIA;

EID: 84860235393     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06305.x     Document Type: Article

References (96)

1. von Behring, E. & S. Kitasato. 1991. The mechanism of diphtheria immunity and tetanus immunity in animals. 1890. Mol. Immunol. 28: 1317, 9-20.
2. Speiser, P. 1957. Observation of a temporary exception to Ehrlich's rule of horror autotoxicus in idiopathic hemolytic anemia (presence of a specific auto-Rh-antibody (D) in a case of acquired hemolytic anemia during a crisis and its disappearance during hormonal therapy. Wien. Klin. Wochenschr. 69: 149-154.
3. Chan, A.C. & P.J. Carter. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10: 301-316.
4. Beck, A., T. Wurch, C. Bailly & N. Corvaia. 2010. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10: 345-352.
5. Elliott, M.J., R.N. Maini, M. Feldmann, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
6. van Dullemen, H.M., S.J. van Deventer, D.W. Hommes, et al. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109: 129-135.
7. Maloney, D.G., A.J. Grillo-Lopez, D.J. Bodkin, et al. 1997. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15: 3266-3274.
8. Maloney, D.G., A.J. Grillo-Lopez, C.A. White, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
9. Hudziak, R.M., G.D. Lewis, M. Winget, et al. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9: 1165-1172.
10. Wong, W.M. 1999. Drug update. Trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer. Cancer. Pract. 7: 48-50.
11. Huber, R., J. Deisenhofer, P.M. Colman, et al. 1976. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 264: 415-420.
12. Franklin, E.C. 1975. Structure and function of immunoglobulins. Acta Endocrinol. Suppl. 194: 77-95.
13. Nimmerjahn, F. & J.V. Ravetch. 2006. Fcgamma receptors: old friends and new family members. Immunity 24: 19-28.
14. Nimmerjahn, F. & J.V. Ravetch. 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19: 239-245.
15. Nimmerjahn, F. & J.V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
16. Ravetch, J.V. & S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275-290.
17. Ravetch, J.V. & F. Nimmerjahn. 2007. Fc receptors and their role in immune regulation and inflammation. In Fundamental Immunology. W.E. Paul, Ed.: 684-705. Lippincott Williams and Wilkins. Philadelphia.
18. Arnold, J.N., M.R. Wormald, R.B. Sim, et al. 2007. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25: 21-50.
19. Kaneko, Y., F. Nimmerjahn & J.V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
20. Feige, M.J., S. Nath, S.R. Catharino, et al. 2009. Structure of the murine unglycosylated IgG1 Fc fragment. J. Mol. Biol. 391: 599-608.
21. Sazinsky, S.L., R.G. Ott, N.W. Silver, et al. 2008. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. USA 105: 20167-20172.
22. Stanley, P., H. Schachter & N. Taniguchi. 2009. N-Glycans. In Essentials of Glycobiology, ed. Ajit Varki et al. Cold Spring Harbor Laboratory Press. New York.
23. Gornik, I., G. Maravic, J. Dumic, et al. 1999. Fucosylation of IgG heavy chains is increased in rheumatoid arthritis. Clin. Biochem. 32: 605-608.
24. Nakagawa, H., M. Hato, Y. Takegawa, et al. 2007. Detection of altered N-glycan profiles in whole serum from rheumatoid arthritis patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 853: 133-137.
25. Guo, N., Y. Liu, Y. Masuda, et al. 2005. Repeated immunization induces the increase in fucose content on antigen-specific IgG N-linked oligosaccharides. Clin. Biochem. 38: 149-153.
26. Ferrara, C., S. Grau, C. Jager, et al. 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc{gamma}RIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108: 12669-12674.
27. Ferrara, C., F. Stuart, P. Sondermann, et al. 2006. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281: 5032-5036.
28. Shields, R.L., J. Lai, R. Keck, et al. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277: 26733-26740.
29. Shinkawa, T., K. Nakamura, N. Yamane, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278: 3466-3473.
30. Shoji-Hosaka, E., Y. Kobayashi, M. Wakitani, et al. 2006. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J. Biochem. 140: 777-783.
31. Natsume, A., M. Wakitani, N. Yamane-Ohnuki, et al. 2005. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J. Immunol. Methods 306: 93-103.
32. Davies, J., L. Jiang, L.Z. Pan, et al. 2001. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74: 288-294.
33. Selman, M.H., E.H. Niks, M.J. Titulaer, et al. 2011. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J. Proteome Res. 10: 143-152.
34. Scallon, B.J., S.H. Tam, S.G. McCarthy, et al. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44: 1524-1534.
35. Anthony, R.M., F. Nimmerjahn, D.J. Ashline, et al. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373-376.
36. Kaneko, Y., F. Nimmerjahn, M.P. Madaio, & J.V. Ravetch. 2006. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203: 789-797.
37. Espy, C., W. Morelle, N. Kavian, et al. 2011. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum 63: 2105-2115.
38. van de Geijn, F.E., M. Wuhrer, M.H. Selman, et al. 2009. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res. Ther. 11: R193.
39. Nimmerjahn, F., R.M. Anthony & J.V. Ravetch. 2007. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl. Acad. Sci. USA 104: 8433-8437.
40. Imbach, P., S. Barandun, V. d'Apuzzo, et al. 1981. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1: 1228-1231.
41. Debre, M., M.C. Bonnet, W.H. Fridman, et al. 1993. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342: 945-949.
42. Nimmerjahn, F. & J.V. Ravetch. 2007. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204: 11-15.
43. Nimmerjahn, F. & J.V. Ravetch. 2008. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26: 513-533.
44. Korganow, A.S., H. Ji, S. Mangialaio, et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10: 451-461.
45. Samuelsson, A., T.L. Towers, & J.V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
46. Crow, A.R., S. Song, J. Freedman, et al. 2003. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102: 558-560.
47. Crow, A.R., S. Song, J.W. Semple, et al. 2003. IVIG induces dose-dependent amelioration of ITP in rodent models. Blood 101: 1658-1659.
48. Anthony, R.M. & J.V. Ravetch. 2010. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30 Suppl 1: S9-S14.
49. Anthony, R.M. & F. Nimmerjahn. 2011. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr. Opin. Organ Transplant. 16: 7-14.
50. Tackenberg, B., I. Jelcic, A. Baerenwaldt, et al. 2009. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. USA 106: 4788-4792.
51. Tackenberg, B., F. Nimmerjahn & J.D. Lunemann. 2010. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J. Clin. Immunol. 30 Suppl 1: S65-S69.
52. Bruhns, P., A. Samuelsson, J.W. Pollard & J.V. Ravetch. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18: 573-581.
53. Anthony, R.M., F. Wermeling, M.C. Karlsson & J.V. Ravetch. 2008. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 105: 19571-19578.
54. Mombaerts, P., J. Iacomini, R.S. Johnson, et al. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68: 869-877.
55. Mebius, R.E. & G. Kraal. 2005. Structure and function of the spleen. Nat. Rev. Immunol. 5: 606-616.
56. Kraal, G. & R. Mebius. 2006. New insights into the cell biology of the marginal zone of the spleen. Int. Rev. Cytol. 250: 175-215.
57. Mebius, R.E., M.A. Nolte & G. Kraal. 2004. Development and function of the splenic marginal zone. Crit. Rev. Immunol. 24: 449-464.
58. Crocker, P.R. 2005. Siglecs in innate immunity. Curr. Opin. Pharmacol. 5: 431-437.
59. Crocker, P.R., S. Kelm, C. Dubois, et al. 1991. Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. Embo. J. 10: 1661-1669.
60. Crocker, P.R., J.C. Paulson & A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7: 255-266.
61. Crocker, P.R. & A. Varki. 2001. Siglecs, sialic acids and innate immunity. Trends Immunol. 22: 337-342.
62. Crocker, P.R., Z. Werb, S. Gordon, et al. 1990. Ultrastructural localization of a macrophage-restricted sialic acid binding hemagglutinin, SER, in macrophage-hematopoietic cell clusters. Blood 76: 1131-1138.
63. Chen, Y., T. Pikkarainen, O. Elomaa, et al. 2005. Defective microarchitecture of the spleen marginal zone and impaired response to a thymus-independent type 2 antigen in mice lacking scavenger receptors MARCO and SR-A. J. Immunol. 175: 8173-8180.
64. Karlsson, M.C., R. Guinamard, S. Bolland, et al. 2003. Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J. Exp. Med. 198: 333-340.
65. Palecanda, A., J. Paulauskis, E. Al-Mutairi, et al. 1999. Role of the scavenger receptor MARCO in alveolar macrophage binding of unopsonized environmental particles. J. Exp. Med. 189: 1497-1506.
66. van der Laan, L.J., E.A. Dopp, R. Haworth, et al. 1999. Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J. Immunol. 162: 939-947.
67. Galustian, C., C.G. Park, W. Chai, et al. 2004. High and low affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and langerin. Int. Immunol. 16: 853-866.
68. Kang, Y.S., Y. Do, H.K. Lee, et al. 2006. A dominant complement fixation pathway for pneumococcal polysaccharides initiated by SIGN-R1 interacting with C1q. Cell 125: 47-58.
69. Kang, Y.S., J.Y. Kim, S.A. Bruening, et al. 2004. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of mouse spleen. Proc. Natl. Acad. Sci. USA 101: 215-220.
70. Kang, Y.S., S. Yamazaki, T. Iyoda, et al. 2003. SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake of the polysaccharide dextran. Int. Immunol. 15: 177-186.
71. Lanoue, A., M.R. Clatworthy, P. Smith, et al. 2004. SIGN-R1 contributes to protection against lethal pneumococcal infection in mice. J. Exp. Med. 200: 1383-1393.
72. Geijtenbeek, T.B., P.C. Groot, M.A. Nolte, et al. 2002. Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens in vivo. Blood 100: 2908-2916.
73. Park, C.G., K. Takahara, E. Umemoto, et al. 2001. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int. Immunol. 13: 1283-1290.
74. Wieland, C.W., E.A. Koppel, J. den Dunnen, et al. 2007. Mice lacking SIGNR1 have stronger T helper 1 responses to mycobacterium tuberculosis. Microbes. Infect. 9: 134-141.
75. Geijtenbeek, T.B., D.S. Kwon, R. Torensma, et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
76. Geijtenbeek, T.B., R. Torensma, S.J. van Vliet, et al. 2000. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100: 575-585.
77. Geijtenbeek, T.B., G.C. van Duijnhoven, S.J. van Vliet, et al. 2002. Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J. Biol. Chem. 277: 11314-11320.
78. Geijtenbeek, T.B., S.J. Van Vliet, E.A. Koppel, et al. 2003. Mycobacteria target DC-SIGN to suppress dendritic cell function. J. Exp. Med. 197: 7-17.
79. Gringhuis, S.I., J. den Dunnen, M. Litjens, et al. 2009. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 10: 1081-1088.
80. Gringhuis, S.I., J. den Dunnen, M. Litjens, et al. 2007. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 26: 605-616.
81. Koppel, E.A., K.P. van Gisbergen, T.B. Geijtenbeek & Y. van Kooyk. 2005. Distinct functions of DC-SIGN and its homologues L-SIGN (DC-SIGNR) and mSIGNR1 in pathogen recognition and immune regulation. Cell. Microbiol. 7: 157-165.
82. Tailleux, L., O. Schwartz, J.L. Herrmann, et al. 2003. DC-SIGN is the major mycobacterium tuberculosis receptor on human dendritic cells. J. Exp. Med. 197: 121-127.
83. van Kooyk, Y. & T.B. Geijtenbeek. 2003. DC-SIGN: escape mechanism for pathogens. Nat. Rev. Immunol. 3: 697-709.
84. van Liempt, E., C.M. Bank, P. Mehta, et al. 2006. Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS Lett. 580: 6123-6131.
85. Anthony, R.M., T. Kobayashi, F. Wermeling & J.V. Ravetch. 2011. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110-113.
86. Schaefer, M., N. Reiling, C. Fessler, et al. 2008. Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection. J. Immunol. 180: 6836-6845.
87. Neill, D.R., S.H. Wong, A. Bellosi, et al. 2010. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367-1370.
88. Wang, J., C.I. Balog, K. Stavenhagen, et al. 2011. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol. Cell. Proteomics 10: M110 004655-1-M110 004655-12.
89. Chintalacharuvu, S.R. & S.N. Emancipator. 1997. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J. Immunol. 159: 2327-2333.
90. Dodel, R., H. Hampel, C. Depboylu, et al. 2002. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 52: 253-256.
91. Rinne, J.O., D.J. Brooks, M.N. Rossor, et al. 2010. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9: 363-372.
92. Fillit, H., G. Hess, J. Hill, et al. 2009. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73: 180-185.
93. Relkin, N.R., P. Szabo, B. Adamiak, et al. 2009. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30: 1728-1736.
94. Fillit, H. 2004. Intravenous immunoglobulins for Alzheimer's disease. Lancet Neurol. 3: 704.
95. Hack, C.E. & P. Scheltens. 2004. Intravenous immunoglobulins: a treatment for Alzheimer's disease? J. Neurol. Neurosurg. Psychiatr. 75: 1374-1375.
96. Saphire, E.O., P.W. Parren, R. Pantophlet, et al. 2001. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293: 1155-1159.